N/A N=5,824 Comparison of Outcomes Between Parenteral and Enteral Nutrition
Deglutition Disorders
Primary: Mortality Calculated From Outcome Section From DPC Database at 90 Days — 359; 287 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=97,507 Outcomes Following Early Parenteral Nutrition Use in Preterm Neonates
Neonatal Death · Prematurity
Primary: Use of Parenteral Nutrition (Project A) — 62145 Participants
N/A N=136 Low Dose Parenteral Fat for Prevention of Parenteral Nutrition Associated Cholestasis in Preterm Neonates
Parenteral Nutrition-Associated Liver Disease
Primary: The Presence of Cholestasis at Age of 28 Days or When Full Enteral Nutrition is Achieved, Whichever is Longer. — 39; 45 participants who developed Cholestasis
Phase 3 N=305 Impact of SPN on Infection Rate, Duration of Mechanical Ventilation & Rehabilitation in ICU Patients
Critically Ill
Primary: Documented Infection Rate — 58; 41 Infections
N/A N=1,059 Enhanced Protein-Energy Provision Via the Enteral Route in Critically Ill Patients
Critically Ill
Primary: Percentage of Prescribed Calories From Energy — 32; 34.2; 43.6; 33.6 percentage of prescription
Phase 3 N=2 Use of Omegaven for Treatment With Parenteral Nutrition Associated Liver Disease
Parenteral Nutrition-related Hepatitis
Primary: Disease Progression as Measured by Serum Levels of Hepatic Enzymes
Phase 3 N=100 Study Comparing a Soybean Oil-Based With an Olive Oil-Based Lipid Emulsion in ICU Patients Requiring TPN
Parenteral Nutrition
Primary: Number of New Nosocomial Infections After 48 Hrs of Parenteral Nutrition (PN) Between the 2 Groups During Their Hospital Stay — 21; 29 number of nosocomial infections
N/A N=2,410 Impact of Early Enteral vs. Parenteral Nutrition on Mortality in Patients Requiring Mechanical Ventilation and Catecholamines
Acute Respiratory Failure · Shock
Primary: Mortality — 422; 443 Participants
Phase 3 N=2 Omegaven as Alternative Parenteral Fat Nutrition
Cholestasis · Cholestasis of Parenteral Nutrition
Primary: Number of Participant With Decrease in Direct Bilirubin Level — 2; 0 Participants
Phase 4 N=94 Oral Nutrition After Regular Radical Cystectomy
Post Cystostomy
Primary: the Postoperative Length of Stay — 18; 14 day — p=<0.001
Phase 3 N=86 Study of Teduglutide Effectiveness in Parenteral Nutrition (PN)-Dependent Short Bowel Syndrome (SBS) Subjects
Short Bowel Syndrome
Primary: Responder — 27; 13 subjects — p=0.002
N/A N=124 Enteral Nutrition as Stress Ulcer Prophylaxis in Critically Ill Patients.
Gastrointestinal Hemorrhage · Clostridium Difficile Colitis
Primary: Number of Subjects With GI Bleeding — 1; 1 participants
N/A N=484 Nutrition and Outcomes of Hematopoietic Cell Transplantation (HCT)
Allogeneic Stem Cell Transplant · Graft Versus Host Disease · Hematologic Malignancy
Primary: Number of Participants With Acute Graft Versus Host Disease (GvHD) at Any Site (Grade II or Above) and Acute GvHD of the Gut of Any Grade — 75; 73; 31; 63 Participants
N/A N=170 TPN-Induced Hyperglycemia: Impact on Clinical Outcome in Intensive Care Unit (ICU) and Non-ICU Patients
Hyperglycemia
Primary: Mortality — 36 mortality rate
Phase 2 N=15 Use of Pancreatic Enzymes in Short Bowel Syndrome
Short Bowel Syndrome
Primary: Change in Coefficient of Fat Absorption — 2.3 percentage of fat absorbed
Phase 2 N=11 Omegaven® in the Treatment of Parenteral Nutrition (PN) Induced Liver Injury
Total Parenteral Nutrition-induced Cholestasis
Primary: Number of Participants With Normalization of Direct Bilirubin — 11 participants
N/A N=100 Clinical Experience With Numeta in Preterm Infants
Premature Infants
Primary: Protein — 3.1; 3.6 g/kg/d
Phase 4 N=303 Intravenous Nutrition in Hospitalized Patients: Comparison of Two Oils
Obstruction · Cancer · Ileus
Primary: Prealbumin — 0.15; 0.16 g/l
Phase 3 N=21 Standard Lipid Therapy vs IVFE Minimization for Prevention of PNALD
Cholestasis
Primary: Rate of Rise of Direct Bilirubin as a Function of Time — 1.033001353; 1.05457485; 1.025504411; 1.049318179 mg/dL/day
Phase 2 N=72 Evaluation of Omegaven™ Parenteral Nutrition in Patients With Total Parenteral Nutrition (TPN)-Induced Cholestasis
Parenteral Nutrition Associated Liver Disease PNALD · Cholestasis
Primary: Number of Patients With Progression to Small Bowel Transplantation. — 19 Participants
Phase 3 N=500 Supplemental Enteral Protein in Critical Illness
Nutrition Disorder · Trauma · Critical Illness
Primary: Serum Concentrations of Transthyretin at 3 Weeks After Injury. — 18.1; 18.9 mg/dl
Phase 4 N=50 Effects of Preoperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy
Pancreatic Cancer · Bile Duct Cancer
Primary: Postoperative Infectious Complication — 7; 15 participants — p=<0.05
N/A N=36 Nutritional Status and Enteral Absorption Capability After Brain Death
Brain Death
Primary: Primary Outcome Measure is IL-6 Level — 565.5; 264.9 pg/ml
N/A N=40 A More Physiological Feeding Process in ICU:the Intermittent Infusion With Semi-solidification of Nutrients
Nutrition, Enteral
Primary: the Ratio of the Enteral Nutrition — 0.98; 0.73 ratio
Phase 4 N=48 Use of Omega-3 Fat Emulsion (Omegaven) in Infants With Parenteral Nutrition Associated Liver Disease
Parenteral Nutrition Associated Liver Disease
Primary: Number of Participants With Resolution of the Direct Hyperbilirubinemia — 29 Participants
Phase 3 N=40 Prospective Randomized Clinical Trial of Intravenous Lipids and Cholestasis
Parenteral Nutrition Associated Cholestasis
Primary: Number of Participants With Parenteral Nutrition Associated Cholestasis — 6; 6 Participants — p=0.94
N/A N=293 Compassionate Use of an Intravenous Fish Oil Emulsion in the Treatment of Liver Injury in Infants
Cholestasis · Cholestasis of Parenteral Nutrition
Primary: Time to Resolution of Parenteral Nutrition Associated Cholestasis Prior to End of Study — 38.02 Days
Phase 3 N=12 Comparing Soybean Oil-Based (Intralipid) With an Olive Oil-Based (ClinOleic) Lipid Emulsion on Healthy Volunteers
Diseases, Metabolic · Insulin Sensitivity
Primary: Flow Mediated Dilation — 10.3; 8.9; 9.2; 9.1 percentage of brachial artery diameter
Phase 3 N=44 Effectiveness of Multicomponent Lipid Emulsion in Preterm Infants Requiring Parenteral Nutrition
Cholestasis
Primary: Incidence of Neonatal Cholestasis — 1; 2 Participants
N/A N=399 Nutrition in Gastroenteropancreatic Neuroendocrine Tumor
Gastroenteropancreatic Neuroendocrine Tumor
Primary: Prevalence of Malnutrition in GEP NET — 247; 152 Participants